VMAT2 Inhibitors Market Size to Hit USD 15.29 Billion by 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on VMAT2 Inhibitors Market

5.1. COVID-19 Landscape: VMAT2 Inhibitors Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global VMAT2 Inhibitors Market, By Drug Type

8.1. VMAT2 Inhibitors Market Revenue and Volume Forecast, by Drug Type

8.1.1. Valbenazine (Ingrezza)

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Deutetrabenazine (Austedo)

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Tetrabenazine (Xenazine) & Others

8.1.3.1. Market Revenue and Volume Forecast

Chapter 9. Global VMAT2 Inhibitors Market, By Application

9.1. VMAT2 Inhibitors Market Revenue and Volume Forecast, by Application

9.1.1. Tardive Dyskinesia (TD)

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Huntington’s Disease (HD)

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Others (Tourette Syndrome/Hyperkinesia)

9.1.3.1. Market Revenue and Volume Forecast

Chapter 10. Global VMAT2 Inhibitors Market, By Route of Administration

10.1. VMAT2 Inhibitors Market Revenue and Volume Forecast, by Route of Administration

10.1.1. Oral (Tablets/Capsules)

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Injectable Solutions

10.1.2.1. Market Revenue and Volume Forecast

Chapter 11. Global VMAT2 Inhibitors Market, By Distribution Channel

11.1. VMAT2 Inhibitors Market Revenue and Volume Forecast, by Distribution Channel

11.1.1. Hospital Pharmacies

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Online Pharmacies

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Retail Pharmacies

11.1.3.1. Market Revenue and Volume Forecast

Chapter 12. Global VMAT2 Inhibitors Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Drug Type

12.1.2. Market Revenue and Volume Forecast, by Application

12.1.3. Market Revenue and Volume Forecast, by Route of Administration

12.1.4. Market Revenue and Volume Forecast, by Distribution Channel

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Drug Type

12.1.5.2. Market Revenue and Volume Forecast, by Application

12.1.5.3. Market Revenue and Volume Forecast, by Route of Administration

12.1.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Drug Type

12.1.6.2. Market Revenue and Volume Forecast, by Application

12.1.6.3. Market Revenue and Volume Forecast, by Route of Administration

12.1.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Drug Type

12.2.2. Market Revenue and Volume Forecast, by Application

12.2.3. Market Revenue and Volume Forecast, by Route of Administration

12.2.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Drug Type

12.2.5.2. Market Revenue and Volume Forecast, by Application

12.2.5.3. Market Revenue and Volume Forecast, by Route of Administration

12.2.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Drug Type

12.2.6.2. Market Revenue and Volume Forecast, by Application

12.2.6.3. Market Revenue and Volume Forecast, by Route of Administration

12.2.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Drug Type

12.2.7.2. Market Revenue and Volume Forecast, by Application

12.2.7.3. Market Revenue and Volume Forecast, by Route of Administration

12.2.7.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Drug Type

12.2.8.2. Market Revenue and Volume Forecast, by Application

12.2.8.3. Market Revenue and Volume Forecast, by Route of Administration

12.2.8.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Drug Type

12.3.2. Market Revenue and Volume Forecast, by Application

12.3.3. Market Revenue and Volume Forecast, by Route of Administration

12.3.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Drug Type

12.3.5.2. Market Revenue and Volume Forecast, by Application

12.3.5.3. Market Revenue and Volume Forecast, by Route of Administration

12.3.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Drug Type

12.3.6.2. Market Revenue and Volume Forecast, by Application

12.3.6.3. Market Revenue and Volume Forecast, by Route of Administration

12.3.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Drug Type

12.3.7.2. Market Revenue and Volume Forecast, by Application

12.3.7.3. Market Revenue and Volume Forecast, by Route of Administration

12.3.7.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Drug Type

12.3.8.2. Market Revenue and Volume Forecast, by Application

12.3.8.3. Market Revenue and Volume Forecast, by Route of Administration

12.3.8.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Drug Type

12.4.2. Market Revenue and Volume Forecast, by Application

12.4.3. Market Revenue and Volume Forecast, by Route of Administration

12.4.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Drug Type

12.4.5.2. Market Revenue and Volume Forecast, by Application

12.4.5.3. Market Revenue and Volume Forecast, by Route of Administration

12.4.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Drug Type

12.4.6.2. Market Revenue and Volume Forecast, by Application

12.4.6.3. Market Revenue and Volume Forecast, by Route of Administration

12.4.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Drug Type

12.4.7.2. Market Revenue and Volume Forecast, by Application

12.4.7.3. Market Revenue and Volume Forecast, by Route of Administration

12.4.7.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Drug Type

12.4.8.2. Market Revenue and Volume Forecast, by Application

12.4.8.3. Market Revenue and Volume Forecast, by Route of Administration

12.4.8.4. Market Revenue and Volume Forecast, by Distribution Channel

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Drug Type

12.5.2. Market Revenue and Volume Forecast, by Application

12.5.3. Market Revenue and Volume Forecast, by Route of Administration

12.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Drug Type

12.5.5.2. Market Revenue and Volume Forecast, by Application

12.5.5.3. Market Revenue and Volume Forecast, by Route of Administration

12.5.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Drug Type

12.5.6.2. Market Revenue and Volume Forecast, by Application

12.5.6.3. Market Revenue and Volume Forecast, by Route of Administration

12.5.6.4. Market Revenue and Volume Forecast, by Distribution Channel

Chapter 13. Company Profiles

13.1. Neurocrine Biosciences, Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial PerDrug Typeance

13.1.4. Recent Initiatives

13.2. Teva Pharmaceutical Industries Ltd.

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial PerDrug Typeance

13.2.4. Recent Initiatives

13.3. Lundbeck A/S

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial PerDrug Typeance

13.3.4. Recent Initiatives

13.4. Bausch Health Companies Inc

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial PerDrug Typeance

13.4.4. Recent Initiatives

13.5. Sun Pharmaceutical Industries Ltd

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial PerDrug Typeance

13.5.4. Recent Initiatives

13.6. Hikma Pharmaceuticals plc

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial PerDrug Typeance

13.6.4. Recent Initiatives

13.7. Dr. Reddy’s Laboratories Ltd.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial PerDrug Typeance

13.7.4. Recent Initiatives

13.8. Lupin Limited

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial PerDrug Typeance

13.8.4. Recent Initiatives

13.9. Aurobindo Pharma

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial PerDrug Typeance

13.9.4. Recent Initiatives

13.10. Hetero Drugs Ltd.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial PerDrug Typeance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

Answer : The VMAT2 inhibitors market size is expected to increase from USD 6.04 billion in 2025 to USD 15.29 billion by 2035.

Answer : The VMAT2 inhibitors market is expected to grow at a compound annual growth rate (CAGR) of around 9.74% from 2026 to 2035.

Answer : The driving factors of the VMAT2 inhibitors market are the rising prevalence of movement disorders, such as tardive dyskinesia, and the increasing adoption of targeted neurological therapies.

Answer : North America region will lead the global VMAT2 inhibitors market during the forecast period 2026 to 2035.